Navigation Links
Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
Date:11/4/2009

EMERYVILLE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, at 9:30 a.m. Mountain Time (8:30 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through December 11, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
4. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
6. Transdel Pharmaceuticals to Present at Two Investor Conferences
7. Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
8. Amylin Pharmaceuticals to Webcast Third Quarter Results
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... cells — optogenetics — is key to exciting advances in the study and ... patterned light projected via free-space optics stimulates small, transparent organisms and excites neurons ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced ... client demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis ... KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s proprietary ...
(Date:12/8/2016)... 8, 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... developing and commercializing products to treat rare diseases where ... it will be hosting an Investor Webcast Event Friday, ... origins of innate defense regulators (IDRs) as a new ... mucositis and the recently announced and published Phase 2 ...
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selector™ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
Breaking Biology Technology:
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
Breaking Biology News(10 mins):